Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...
Gout is a more common condition than you might presume. According to a 2024 analysis in The Lancet, more than 58 million individuals struggle with this type of arthritis that arises from a buildup of ...
The MarketWatch News Department was not involved in the creation of this content. -- Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback